Donald John Birkett
#136,653
Most Influential Person Now
Donald John Birkett's AcademicInfluence.com Rankings
Donald John Birkettbiology Degrees
Biology
#9416
World Rank
#12620
Historical Rank
Biochemistry
#1437
World Rank
#1561
Historical Rank
Download Badge
Chemistry Biology
Donald John Birkett's Degrees
- PhD Biochemistry University of California, Berkeley
- Masters Chemistry Stanford University
Why Is Donald John Birkett Influential?
(Suggest an Edit or Addition)Donald John Birkett's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The characterization of two specific drug binding sites on human serum albumin. (1975) (1453)
- Further characterization of specific drug binding sites on human serum albumin. (1976) (1302)
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. (1998) (853)
- The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. (1996) (641)
- Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. (1993) (345)
- Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. (1993) (239)
- Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. (1994) (227)
- Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. (1988) (210)
- Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. (1991) (206)
- Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. (1994) (191)
- Influence of sex and oral contraceptive steroids on paracetamol metabolism. (1983) (175)
- Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. (2001) (167)
- Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines (1986) (163)
- Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. (1986) (158)
- Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. (1994) (155)
- The reactivity of SH groups with a fluorogenic reagent (1970) (147)
- Nonspecific binding of drugs to human liver microsomes. (2000) (143)
- Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. (1993) (142)
- Quantitative assessment of caffeine partial clearances in man. (1986) (139)
- Structural requirements for drug binding to site II on human serum albumin. (1983) (137)
- Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. (1993) (133)
- Mechanism of action of paracetamol protective agents in mice in vivo. (1984) (126)
- Cigarette smoking and theophyiiine clearance and metabolism (1981) (125)
- Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. (1996) (123)
- Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers (1990) (115)
- The use of caffeine as a metabolic probe for human drug metabolizing enzymes. (1996) (114)
- Effects of allopurinol on theophylline metabolism and clearance (1979) (113)
- Characterisation of theophylline metabolism in human liver microsomes. (1987) (111)
- Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. (1988) (111)
- Generics - equal or not? (2003) (109)
- Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. (1991) (106)
- Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. (1992) (101)
- The xenobiotic inhibitor profile of cytochrome P4502C8. (2000) (95)
- Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. (2010) (94)
- A cost-effectiveness approach to drug subsidy and pricing in Australia. (2001) (94)
- Allelic and functional variability of cytochrome P4502C9. (1997) (93)
- Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. (2003) (92)
- Effect of age on patterns of theophylline metabolism (1980) (89)
- Effects of fatty acids on two specific drug binding sites on human serum albumin. (1977) (89)
- Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways (1984) (87)
- Probes for the conformational transitions of phosphorylase b. Effect of ligands studied by proton relaxation enhancement, fluorescence and chemical reactivities. (1971) (86)
- In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. (1994) (85)
- Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. (1996) (84)
- Pharmacokinetics Made Easy (1999) (83)
- Spectroscopic techniques in the study of protein binding. A fluorescence technique for the evaluation of the albumin binding and displacement of warfarin and warfarin‐alcohol (1975) (81)
- Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. (1991) (76)
- Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulfaphenazole (1977) (76)
- Paracetamol metabolism in pregnancy. (1986) (74)
- Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. (1986) (74)
- Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. (1995) (69)
- Action of urea on human alkaline phosphatases: with a description of some automated techniques for the study of enzyme kinetics. (1967) (68)
- Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues. (1989) (64)
- Lidocaine disposition—Sex differences and effects of cimetidine (1984) (63)
- Characterization of chloroquine plasma protein binding in man. (1983) (61)
- High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. (1993) (60)
- The action of EDTA on human alkaline phosphatases. (1967) (60)
- Metabolism of benzo[a]pyrene. Effect of 3-methylcholanthrene pretreatment on metabolism by microsomes from lungs of genetically "responsive" and "nonresponsive" mice. (1977) (60)
- Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. (2000) (58)
- Protein Binding of some Non-steroidal Anti-inflammatory Drugs in Rheumatoid Arthritis (1982) (57)
- In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. (1988) (56)
- Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. (1988) (56)
- Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. (2003) (55)
- Serum Alkaline Phosphatase in Pregnancy: an Immunological Study (1966) (55)
- Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. (1989) (55)
- Intestinal alkaline phosphatase in human serum. (1967) (55)
- Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. (2007) (53)
- Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia (2001) (53)
- Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. (1984) (53)
- Variability of L-dopa absorption in man. (1974) (53)
- Comparison of paracetamol metabolism in young adult and elderly males (2004) (51)
- Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid. (1983) (51)
- Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. (1988) (48)
- Theophylline Metabolism by Human, Rabbit and Rat Liver Microsomes and by Purified Forms of Cytochrome P450 (1988) (48)
- Flavin-containing monooxygenase activity in human liver microsomes. (1987) (47)
- The effects of N-B transition of human serum albumin on the specific drug-binding sites. (1982) (47)
- Metoclopramide, gastric emptying and L-dopa absorption. (1974) (47)
- Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism (1984) (46)
- Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene. (1996) (46)
- Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. (1993) (45)
- Comparison of theophylline and theobromine metabolism in man. (1985) (44)
- Co-regulation of phenytoin and tolbutamide metabolism in humans. (1992) (44)
- Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism (1994) (43)
- Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. (1994) (42)
- Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. (1990) (41)
- Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. (1983) (41)
- Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. (1990) (41)
- Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine. (1989) (40)
- Pharmacokinetics made easy: Therapeutic drug monitoring (1997) (37)
- Effects of tricyclic antidepressants on drug metabolism (1975) (37)
- Theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways. (1984) (37)
- Spectroscopic techniques in the study of protein binding: the use of 1-anilino-8-naphthalenesulphonate as a fluorescent probe for the study of the binding of iophenoxic and iopanoic acids to human serum albumin. (1973) (37)
- Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. (1988) (35)
- The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography. (1980) (35)
- The fatty acid content and drug binding characteristics of commercial albumin preparations. (1978) (34)
- Polymorphic hydroxylation of perhexiline in vitro. (2003) (34)
- A SIMPLE HPLC ASSAY FOR URINARY PARACETAMOL METABOLITES AND ITS USE TO CHARACTERIZE THE C3H MOUSE AS A MODEL FOR PARACETAMOL METABOLISM STUDIES (1984) (33)
- Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. (1998) (32)
- RACEMATES OR ENANTIOMERS: REGULATORY APPROACHES (1989) (31)
- Pattern of non‐steroidal anti‐inflammatory drug use in Australia 1990–1994 A report from the Drug Utilization Sub‐Committee of the Pharmaceutical Benefits Advisory Committee (1996) (31)
- Cyclosporin-verapamil interaction. (1988) (31)
- Nonlinear Metabolic Disposition of Theophylline (1984) (30)
- Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. (1985) (30)
- Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. (1998) (29)
- Theobromine metabolism in man. (1982) (29)
- Profiles of antibacterial drug use in Australia and trends from 1987 to 1989: A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee (1991) (29)
- Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. (2004) (28)
- Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. (1983) (27)
- Biochemical validation of self-reported caffeine consumption during caffeine fading (1988) (27)
- The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. (1980) (27)
- Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle. (1989) (26)
- Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man. (1985) (25)
- The effect of ranitidine on the disposition of lignocaine. (1985) (25)
- Single Oral Dose Pharmacokinetics of Erythromycin and Roxithromycin and the Effects of Chronic Dosing (1990) (25)
- Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9 (2004) (23)
- Analysis of D-penicillamine in plasma by fluorescence derivatisation with N-[p-(2-benzoxazolyl)-phenyl] maleimide and high-performance liquid chromatography. (1983) (23)
- Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline. (1988) (22)
- High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. (1993) (21)
- Mechanism of inactivation of rabbit muscle glyceraldehyde 3-phosphate dehydrogenase by ethacrynic acid. (1973) (20)
- 6-MERCAPTOPURINE-RELATED LEUCOPENIA AND IN VIVO XANTHINE OXIDASE ACTIVITY (1986) (20)
- In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy (2010) (20)
- Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? (2001) (20)
- Reversible metabolism of D-penicillamine in the rat. (1984) (20)
- Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. (2010) (20)
- Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine. (1988) (19)
- A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells (2014) (18)
- The Flinders experiment in medical education revisited (1991) (18)
- Immunohistochemical localization and quantitation of NADPH-cytochrome P-450 reductase in human liver. (1987) (17)
- Identification and quantitation in human liver of cytochromes P-450 analogous to rabbit cytochromes P-450 forms 4 and 6. (1988) (17)
- The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. (2006) (17)
- Differential effects of cimetidine on theophylline metabolic pathways (2004) (17)
- Perturbation of paracetamol urinary metabolic ratios by urine flow rate. (1992) (16)
- Liquid-chromatographic determination of 5-fluorocytosine. (1980) (16)
- The effect of sulphinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination (2004) (15)
- Dose, plasma concentration and response relationships of D-penicillamine in patients with rheumatoid arthritis. (1984) (15)
- Localisation of aryl sulfotransferase expression in human tissues using hybridisation histochemistry and immunohistochemistry. (1998) (15)
- Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. (1996) (14)
- Changes to the Pharmaceutical Benefits Advisory Committee (2001) (14)
- Relationships between plasma theophylline clearance, liver volume and body weight in children and adults (2004) (13)
- The kinetics of amitriptyline following single oral dose administration to man. (1978) (13)
- Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. (1987) (12)
- Metabolic disposition of the methylxanthines in man (1982) (11)
- A fluorescent probe for the dimer to tetramer conversion of glycogen phosphorylases a and b (1970) (11)
- Pharmacokinetics made easy 9: Non-linear pharmacokinetics (1994) (11)
- Metabolic drug interactions--a critical review. (1975) (10)
- Simultaneous determination of pentoxifylline and its hydroxy metabolite in plasma by high-performance liquid chromatography. (1981) (10)
- 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. (2003) (9)
- Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. (2003) (9)
- Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes (2011) (9)
- INTERACTION OF SOME DRUGS, METAL IONS, AND ALCOHOLS WITH RAT LIVER MICROSOMES AS STUDIED WITH A FLUORESCENT PROBE (1974) (9)
- The formation of proximate carcinogens from three polycyclic aromatic compounds by human liver microsomes. (1992) (8)
- Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. (1995) (8)
- Quantitation of plasma warfarin levels by gas chromatography chemical ionization mass spectrometry. (1979) (8)
- Protein binding of GP53,633: a basic non-steroidal anti-inflammatory drug. (1982) (8)
- Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. (1993) (8)
- 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect. (1991) (8)
- Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children (2004) (8)
- Warfarin and warfarin-alcohol levels in anticoagulated patients. (1979) (8)
- Metabolism of 2-acetylaminofluorene in cultured human lymphocytes. (1987) (8)
- Baculovirus-mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase: optimization of protein expression. (1998) (8)
- Effect of cimetidine on paracetamol activation in mice. (1984) (8)
- Mechanism of formation of 6-amino-5-(N-methylformylamino)-1-methyluracil and 3,7-dimethyluric acid from theobromine in the rat in vitro: involvement of cytochrome P-450 and a cellular thiol. (1990) (8)
- Pharmacokinetics made easy 11 Designing dose regimens (1996) (8)
- The misuse of urinary metabolite excretion data in drug metabolism studies. (1993) (7)
- Pharmacokinetics made easy 10 Pharmacodynamics - the concentration-effect relationship (1995) (7)
- Daring to dream : the future of Australian health care (2001) (7)
- Plasma quantitation of warfarin and warfarin alcohol by gas chromatography chemical ionization mass spectrometry in patients on warfarin maintenance therapy. (1979) (7)
- Continuous determination of enzyme activity during heat inactivation. (1966) (6)
- The interactions between iophenoxic acid, iopanoic acid, bilirubin and human serum albumin as studied by fluorescence and Sephadex gel filtration. (1976) (6)
- Access to medicines and high‐quality therapeutics: global responsibilities for clinical pharmacology (2005) (6)
- Prescription use by patients with concession cards (1998) (6)
- Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. (1987) (6)
- Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT. (1984) (6)
- New Uses for Allopurinol (1994) (5)
- Interaction between cimetidine and theophylline in smokers and non-smokers (1981) (5)
- Nonspecific binding of drugs to human liver microsomes (2000) (4)
- IMMUNOCHEMICAL AND CATALYTICAL CHARACTERIZATION OF THE HUMAN LIVER NADPH‐CYTOCHROME P450 REDUCTASE (1989) (4)
- Development of an Australian Drug Utilisation Database (1993) (4)
- Fluorescent probe studies of albumin binding sites (1980) (4)
- Interaction of sulphinpyrazone with warfarin (2004) (4)
- Analysis of low theophylline concentrations using the Abbott TDx. (1991) (4)
- Recent changes in the profile of prescription NSAID use in Australia (2000) (4)
- Effects of time of dose in relation to food on the bioavailability of Theo‐Dur Sprinkle at steady state in asthmatic children (1989) (4)
- MULTIPLE DRUG INTERACTIONS WITH PHENYTOIN (1977) (3)
- The importance of unbound drug. (1985) (2)
- [Pyrophosphatase activity of alkaline phosphatase]. (1967) (2)
- Radiometric high-performance liquid chromatographic procedure for the determination of theobromine metabolites in microsomal incubations. (1988) (2)
- The reactivity of group-specific chromophoric reagents. (1970) (2)
- A case for generic prescribing? (1983) (2)
- Interfering ribonucleic acids that suppress expression of multiple unrelated genes (2009) (2)
- The xenobiotic inhibitor profile of cytochrome P4502C8 (2000) (2)
- Structure-activity relationships for protein binding of a series of basic non-steroidal anti-inflammatory drugs. (1991) (1)
- Protein binding of non-steroidal antiinflammatory drugs in rheumatoid arthritis (1980) (1)
- Comparison of diurnal variation of three sustained release theophylline preparations in asthmatic children (1986) (1)
- AVAILABILITY OF SCHEDULE 3 PREPARATIONS FROM COMMUNITY PHARMACIES (1980) (1)
- The effect of fatty acids on drug binding sites on human serum albumin (1978) (1)
- Determinants of the non-specific binding of drugs to human liver microsomes (2004) (1)
- Tracking high users of pethidine after restrictions were placed on PBS supply (1999) (1)
- Economic analysis: a response (1999) (1)
- Patterns of drug metabolism in man (1979) (1)
- AVAILABILITY OF SCHEDULE 3 PREPARATIONS FROM COMMUNITY PHARMACIES (1979) (0)
- Steady-state bioavailability of a slow release theophylline formation in children with acute asthma (1980) (0)
- Comparative pharmacokinetics of quinine and quinidine in man (1978) (0)
- Protein binding of a new, basic non-steroidal anti-inflammatory drug (NSAID), GP 53,633, and its major metabolite (1981) (0)
- THEEFFECTOF METOCLOPRAMIDE AND ATROPINEON THE ABSORPTION OF ORALLYADMINISTEREDMEXILETINE (1980) (0)
- Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report) (2021) (0)
- Protein-binding during haemodialysis (1979) (0)
- Fundamentals of clinical pharmacology.: 10. Pharmacological basis of adverse drug effects (1980) (0)
- SECONDARY METABOLISMOFTHEOPHYLLINE BIOTRANSFORMATIONPRODUCTSINMAN-ROUTE OF FORMATION OF1-METHYLURICACID (1983) (0)
- CHARACTERIZATION OFCHLOROQUINE PLASMA PROTEIN BINDINGINMAN (1983) (0)
- The reactivity of group-specific chromophoric reagents. (1970) (0)
- In reply (1996) (0)
- The practical application of drug assays in general practice. (1980) (0)
- Flavin-containing monooxygenase activity in human liver microsomes. (1986) (0)
- Temperature transitions of the microsomal hydroxylation system (1977) (0)
- Urine caffeine concentrations to control caffeine intake during competitive sports events (1990) (0)
- Caffeine formation during treatment of neonatal apnoea with theophylline (1982) (0)
- Flerkomponentnukleinsyreenzymer and methods of use thereof (2006) (0)
- The relationship between the methylhydroxylation off tolbutamide and the 4-hydroxylation off phenytoin in human liver microsomes (1990) (0)
- Clinical pharmacology of GP53,633—a new non-steroidal anti-inflammatory drug — in patients with rheumatoid arthritis (1984) (0)
- The multicomponent nukleinsyreenzymer and methods for their use (2006) (0)
- Mechanism of inhibition of tolbutamide metabolism by phenylbutazone and oxyphenbutazone (1978) (0)
- Population screening of tolbutamide hydroxylase activity (1990) (0)
- Drug Literature Abstracts (2012) (0)
- Comprar Pharmacokinetics Made Easy | Donald Birkett | 9780070285279 | Mcgraw-Hill Education (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Donald John Birkett?
Donald John Birkett is affiliated with the following schools:
